Status:
NOT_YET_RECRUITING
Anlotinib and Benmelstobart in DTC
Lead Sponsor:
Fudan University
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is a multicenter, open-label, phase II study to evaluate the efficacy and safety of Benmelstobart in combination with Anlotinib as a second-line treatment for locally advanced or metastatic...
Eligibility Criteria
Inclusion
- The patient voluntarily agrees to participate in this study and has signed the informed consent form;
- Age: ≥18 years, regardless of gender;
- Histologically confirmed differentiated thyroid cancer;
- Unresectable or borderline unresectable locally advanced thyroid cancer and/or metastatic thyroid adenocarcinoma;
- Failure of first-line treatment (failure to achieve partial or complete response) or disease progression after first-line treatment;
- At least one measurable lesion;
- ECOG PS: 0-2;
- Expected survival period ≥12 weeks;
- Patient agrees to undergo tumor tissue biopsy/surgery at the time of enrollment;
- Normal function of major organs;
- Willingness to use reliable contraceptive methods during the trial. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment.
- The subject voluntarily agrees to participate in this study, signs the informed consent form, demonstrates good compliance, and cooperates with follow-up.
Exclusion
- Presence of other active malignancies within the past 5 years or concurrently. Patients with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc., may be enrolled.
- Use of other antitumor therapies (including but not limited to chemotherapy, radiotherapy, etc.) within 28 days prior to the first administration of the study drug. Thyrotropin (TSH) suppressive therapy is excluded.
- Prior treatment with immune checkpoint inhibitors (including but not limited to nivolumab, pembrolizumab, toripalimab, sintilimab, etc.).
- Any severe or uncontrolled systemic disease, as determined by the investigator, including poorly controlled hypertension (systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg) despite medication, uncontrolled diabetes, poorly managed cardiac disease, and signs of active bleeding.
- Known history of severe allergy to any monoclonal antibody or anti-angiogenic targeted drug.
- Presence of uncontrolled infection at the time of screening.
- Pregnant or lactating women.
- Refusal to undergo tumor tissue biopsy at the time of enrollment.
- Other conditions considered by the treating physician as unsuitable for inclusion.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT07193186
Start Date
October 1 2025
End Date
December 31 2030
Last Update
September 25 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.